Advanced

Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine

Nilsson-Ehle, Peter LU ; Ekberg, M; Fridstrom, P; Ursing, D and Lins, L E (1988) In Acta Medica Scandinavica 224(2). p.131-134
Abstract
Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on... (More)
Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on clonidine). Adverse effects were mild and tolerable, and consisted mainly of dryness of the mouth. We conclude that clonidine lowers the blood pressure in patients with type II diabetes without any adverse effects on glycemic control or plasma lipoproteins. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Medica Scandinavica
volume
224
issue
2
pages
131 - 134
publisher
Norstedts
external identifiers
  • pmid:3048053
  • scopus:0023810807
ISSN
0001-6101
language
English
LU publication?
yes
id
5990ed6f-ddde-46cc-ad70-9138258d6534 (old id 1104326)
date added to LUP
2008-08-07 15:34:04
date last changed
2017-01-01 06:47:14
@article{5990ed6f-ddde-46cc-ad70-9138258d6534,
  abstract     = {Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on clonidine). Adverse effects were mild and tolerable, and consisted mainly of dryness of the mouth. We conclude that clonidine lowers the blood pressure in patients with type II diabetes without any adverse effects on glycemic control or plasma lipoproteins.},
  author       = {Nilsson-Ehle, Peter and Ekberg, M and Fridstrom, P and Ursing, D and Lins, L E},
  issn         = {0001-6101},
  language     = {eng},
  number       = {2},
  pages        = {131--134},
  publisher    = {Norstedts},
  series       = {Acta Medica Scandinavica},
  title        = {Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine},
  volume       = {224},
  year         = {1988},
}